二甲双胍与妇科肿瘤关系的研究现状

Current status of research on the relationship between metformin and gynecological tumor

二甲双胍是双胍类药物的代表，是目前世界上治疗2型糖尿病的一线用药。有相当数量的研究表明其可抑制肝癌、胰腺癌、乳腺癌等多种恶性肿瘤的发生和发展。在妇科领域，多年来随着妇科肿瘤的早期发现率及手术方式的提高，有关妇科肿瘤的预后及控制病情进展的研究成为当代妇科临床及科研人员的研究热点，并已有关于二甲双胍与妇科肿瘤关系的研究成功报道。由此可见二甲双胍在妇科肿瘤领域有着相当乐观的发展前景及研究空间。本文将对二甲双胍在妇科肿瘤领域中的最新研究成果及进展作一综述。

Metformin, a representative of biguanides, is currently the world＇s first line of treatment for type 2 diabetes. A considerable number of studies have showed that it can inhibit the occurrence and development of liver cancer, pancreatic cancer, breast cancer and other malignant tumors. In the field of gynecology, over the years, with the early detection rate of gynecological tumors and the improvement of surgical methods, the research on the prognosis and control of gynecological tumor has become a hot research topic in clinical and scientific research, and has been related to the research on the relationship between metformin and gynecological tumor. This shows that metformin in the field of gynecological cancer has a very optimistic prospects and research space. In this review, we will discuss the recent progress in the study of metformin in the field of gynecologic oncology.